BNGO Earnings Prediction
The chart below shows how BNGO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BNGO sees a +7.22% change in stock price 10 days leading up to the earnings, and a +6.84% change 10 days following the report. On the earnings day itself, the stock moves by -2.40%. This data can give you a slight idea of what to expect for the next quarter's release.
BNGO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
8.16M
-23.86%
34.41%
Gross Margin
41.86%
84.08%
-130.10%
Operating Margin
227.77%
197.86%
-161.13%
Net Margin
-246.54%
-39.78%
-66.16%
EPS
-5.29K
-480625.45%
1016819.23%
No Data Available
BNGO Earnings Analysis
Bionano Genomics Inc Corporation (BNGO.O) Earnings Conference Call
Positive
Revenue and Margin Improvement: Total revenue for Q4 2024 was $8.2 million, with a significant improvement in GAAP gross margin to 42%, up from 23% in Q4 2023.
Gross Margin Improvement: Non-GAAP gross margin for Q4 2024 was also 42%, compared to 24% in Q4 2023, indicating improved profitability.
Operating Expenses Reduction: GAAP operating expenses decreased to $15.4 million in Q4 2024 from $27.4 million in Q4 2023, reflecting effective cost management.
Extended Cash Runway: Cash runway extended into Q1 2026, supported by $3.6 million raised from ATM sales and a $10 million registered direct offering in January 2025.
Product Revenue Increase: Product revenues for the full year 2024 increased by 1% to $27 million, with consumables sales rising by 14% to $12.8 million and software sales increasing by 11% to $6.2 million.
Regional Sales Growth: Sales in the Americas and EMEA regions grew by 9% and 10% respectively in 2024, showcasing strong market demand.
Nano Channel Array Sales Growth: Sold 30,307 nano channel array flow cells in 2024, a 15% increase over the previous year, indicating growing adoption of their technology.
Customer Growth Impact: VIA software installations increased significantly, from 40 to over 160 OGM customers, enhancing revenue potential and customer productivity.
OGM Publication Growth: Publications related to OGM increased by 19% in 2024, with a notable 39% growth in clinical research and cell and gene therapy publications, supporting the technology's credibility.
CPT Code Milestone for OGM: The establishment of a Category 1 CPT code for OGM use in hematologic malignancies by the American Medical Association is a significant milestone for reimbursement and market acceptance.
Negative
Q4 Revenue Decline: Total revenue for Q4 2024 was $8.2 million, a decrease of 24% compared to Q4 2023, which included $2 million from discontinued clinical services.
Gross Margin Analysis: GAAP gross margin for Q4 2024 was 42%, but full year 2024 GAAP gross margin was only 1%, down from 26% in 2023 after one-time adjustments.
Operating Expense Analysis: Despite a decrease in operating expenses, the company reported a significant GAAP operating expense of $15.4 million for Q4 2024, compared to $27.4 million in Q4 2023, indicating ongoing high costs.
Liquidity Concerns: Cash, cash equivalents, and available securities as of December 31, 2024, were $20.9 million, with $11.4 million subject to restrictions, raising concerns about liquidity.
Debt Restructuring Concerns: The company modified the terms of its senior secured convertible debentures, indicating potential financial distress and reliance on debt restructuring.
Market Strategy Shift: The shift in go-to-market strategy to conserve cash and focus on existing customers suggests challenges in acquiring new customers and growing the business.
Margin Volatility and Uncertainty: The company expects ongoing volatility in margins and has refrained from providing guidance on margin, indicating uncertainty in financial performance going forward.
BNGO FAQs
How does BNGO typically perform around its earnings report dates?
Is Bionano Genomics Inc (BNGO) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BNGO Earning Call Sentiment
Bionano Genomics, Inc. (BNGO) Q4 2024 Earnings Call Transcript
BNGO.O
20.97%Positive
The earnings call summary reveals several concerns: declining quarterly revenue, competitive pressures, and regulatory challenges. Despite a strong gross margin improvement, the lack of a shareholder return plan and uncertainty in revenue outlook due to economic factors and cash conservation risks weigh negatively. The Q&A section highlights management's evasiveness on key metrics, such as net install base, adding to uncertainty. The positive feedback on new product initiatives and potential growth in user groups is overshadowed by these concerns. Overall, the sentiment leans negative, suggesting a potential stock price decline.
